Speaker illustration

Mr Daniel Harris

Swansea University, Swansea (United Kingdom of Great Britain & Northern Ireland)

Early discontinuation of P2Y12 antagonist and adverse clinical outcomes post percutaneous coronary intervention

Event: EuroPrevent 2018

Topic: Coronary Artery Disease, Other

Session: Coronary artery disease, acute coronary syndromes, acute cardiac care


ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb